Treatment | FEV1 | FEV1/FVC | WBC (K/mL) | Platelets (K/mL | Fasting glucose (mg/dL) | |||||
Quercetin dose (mg/day) | At run-in (%) | Post- treatment (%) | At run-in (%) | Post- treatment (%) | At run-in | Post- treatment | At run-in | Post- treatment | At run-in | Post- treatment |
Placebo | 38.8 | 35.0 | 51.0 | 63.6 | 5.4 | 6.4 | 236 | 223 | 90 | 99 |
Placebo | 40.9 | 40.3 | 63.6 | 63.3 | 5.5 | 4.6 | 170 | 167 | 89 | 126 |
Placebo | 53.3 | 50.7 | 70.6 | 74.6 | 5.6 | 5.8 | 135 | 130 | 111 | 84 |
500 mg/day | 75.7 | 79.3 | 79.8 | 82.4 | 5 | 5 | 259 | 266 | 89 | 98 |
500 mg/day | 46.7 | 43.2 | 66.8 | 63.9 | 10.6 | 11.1 | 236 | 268 | 138 | 89 |
1000 mg/day | 53.0 | 47.3 | 89.0 | 92.5 | 6.2 | 5.5 | 144 | 153 | 122 | 125 |
1000 mg/day | 49.5 | 50.5 | 53.1 | 49.9 | 5.5 | 4.6 | 164 | 178 | 234 | 139 |
2000 mg/day | 53.9 | 55.5 | 67.1 | 66.0 | 8.3 | 8.3 | 280 | 298 | 143 | 140 |
2000 mg/day | 50.0 | 47.3 | 52.0 | 56.4 | 5.7 | 5.3 | 271 | 277 | 150 | 91 |
FEV1, forced expiratory volume in one second; FVC, forced vital capacity; WBC, white blood cell.